IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Drug-Induced Liver Injury (DILN)Network Retrospective (ILIAD)
This study is currently recruiting participants.
Verified April 2017 by Duke University
Sponsor:
Duke University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00360646
First received: August 2, 2006
Last updated: July 25, 2017
Last verified: April 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI caused by four specific drugs, and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies. A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.
| Condition |
|---|
| Drug Induced Liver Injury |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Control Time Perspective: Retrospective |
| Official Title: | Idiosyncratic Liver Injury Associated With Drugs (ILIAD): A Retrospective Study |
Further study details as provided by Duke University:
Biospecimen Retention: Samples With DNA
Detailed Description:
Samples with DNA
| Estimated Enrollment: | 200 |
| Study Start Date: | September 2004 |
| Estimated Study Completion Date: | June 2018 |
| Estimated Primary Completion Date: | June 2018 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Subjects with liver injury |
| Subjects without liver injury |
Detailed Description:
Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate research into DILI, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently established the Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with any drugs (ILIAD) and HDS agents, and to collect, immortalize and store serum, DNA, and lymphocytes from these patients (hereafter referred to as the "ILIAD protocol"). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the basis for susceptibility to severe idiosyncratic DILI.
The network will initially identify people who have developed DILI onset beyond 6 months of enrollment due to all drugs or HDS/CAM cases that did not meet the entrance criteria for the Prospective study.
The specific aims are as follows:
- Establish and maintain a clinical database of these people that contains relevant clinical data.
- Establish a bank of biological specimens (serum, DNA, and immortalized lymphocytes) prepared from cases and control in the clinical database.
- Maintain a registry including yearly updated contact information of the subjects enrolled in the clinical database so that it is possible to recontact these individuals at a later date to offer participation in studies which are not part of the current proposal.
Eligibility| Ages Eligible for Study: | 2 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with liver injury ascribed to any drug or HDS/CAM agent which the DILI onset date occurred beyond six months from enrollment.
Criteria
Inclusion Criteria:
Screening Criteria
To be included in the ILIAD registry, the following criteria must be satisfied:
- The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury;
- The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;
- Evidence of injury that is known or suspected to be related to consumption of a drug or HDS/CAM product
- The subject is taking only one of these drugs or HDS agent(s) in the period leading up to the onset of the qualifying DILI episode;
- Have clinically important DILI defined in terms of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (Alk Phos).
- Sufficient documentation of the event for the Causality Committee to make a determination.
Exclusion Criteria:
Subjects will be excluded according to the following criteria:
- are not willing to have medical information and blood samples taken;
- are unable to adequately give informed consent to participate in the study including the blood draw for the genetic component;
- age < 2 years old at the time of study enrollment (due to blood volume requirements).
- Have a competing cause of liver injury such as hepatic ischemia that the investigator felt to be the primary reason for the observed liver injury. Known, pre-existing autoimmune hepatitis; primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease. Subjects are excluded due to acetaminophen hepatoxicity or liver transplant or allogeneic bone marrow transplant prior to development of drug-CAM induced liver injury.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00360646
Please refer to this study by its ClinicalTrials.gov identifier: NCT00360646
Contacts
| Contact: Kathy M Galan, RN | 919-668-8579 | Galan006@mc.duke.edu | |
| Contact: Theresa O'Riellly | 919-668-8465 | theresa.o'rielly@duke.edu |
Locations
| United States, California | |
| University of Southen California | Recruiting |
| Los Angeles, California, United States, 90033 | |
| Contact: Susan Milstein, RN 323-442-2699 smilstei@usc.edu | |
| Contact: Neil Kaplowitz, MD 323-442-5576 kaplowit@usc.edu | |
| Principal Investigator: Andrew Stolz, MD | |
| United States, Indiana | |
| Indiana University | Recruiting |
| Indianapolis, Indiana, United States, 46202-5111 | |
| Contact: Audrey Corne, RN, CCRN 317-278-3062 acorne@iupui.edu | |
| Principal Investigator: Naga P Chalasani, MD | |
| United States, Maryland | |
| NIH Clinical Site | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: Beverly Niles 301-451-0659 beverly.niles@nih.gov | |
| Contact: Chris Koh, MD christopher.koh@nih.gov | |
| United States, Michigan | |
| University of Michigan | Recruiting |
| Ann Arbor, Michigan, United States, 48109-0362 | |
| Contact: Kendall Dabois 734-644-2277 kendalld@umich.edu | |
| Principal Investigator: Robert J Fontana, MD | |
| United States, New York | |
| Icahn School of Medicine at Mount Sinai | Recruiting |
| New York, New York, United States, 10029 | |
| Contact: Stephanie Pagan 212-241-8035 stephanie.pagan@mssm.edu | |
| Contact: Jospeh Odin, MD 212-241-8035 joseph.odin@mountsinai.org | |
| United States, North Carolina | |
| Univeristy of North Carolina at Chapel Hill | Recruiting |
| Chapel Hill, North Carolina, United States, 27599-7600 | |
| Contact: Tracy Russell 919-843-2376 trussell@med.unc.edu | |
| Principal Investigator: Paul B Watkins, MD | |
| United States, Pennsylvania | |
| Albert Einstein | Recruiting |
| Philadelphia, Pennsylvania, United States, 19141 | |
| Contact: Manisha Verma, MD MPH 215-456-1026 Vermam@einstein.edu | |
| Principal Investigator: Victor J. Navarro, MD | |
Sponsors and Collaborators
Duke University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
| Principal Investigator: | Huiman X. Barnhart, PhD | Duke University |
| Study Chair: | Paul Watkins, MD | University of North Carolina, Chapel Hill |
More Information
Additional Information:
Publications:
| Responsible Party: | Duke University |
| ClinicalTrials.gov Identifier: | NCT00360646 History of Changes |
| Other Study ID Numbers: |
Pro00017208 2U01-DK065176-11Revised+ Pro00011992 |
| Study First Received: | August 2, 2006 |
| Last Updated: | July 25, 2017 |
Keywords provided by Duke University:
|
LIVER DIS CHEM IND Drugs Drug induced liver injury phenotype |
cholestatic liver injury hepatocellular liver injury mixed liver injury genotype |
Additional relevant MeSH terms:
|
Wounds and Injuries Drug-Induced Liver Injury Liver Diseases Digestive System Diseases Drug-Related Side Effects and Adverse Reactions |
Chemically-Induced Disorders Poisoning Liver Extracts Hematinics |
ClinicalTrials.gov processed this record on September 18, 2017